As of today, there is no antiviral for the treatment of the SARS-CoV-2 infection, and the development of a vaccine might take several months or even years. The structural superposition of the hepatitis C virus polymerase bound to sofosbuvir, a nucleoside analog antiviral approved for hepatitis C virus infections, with the SARS-CoV polymerase shows that the residues that bind to the drug are present in the latter. Moreover, a multiple alignment of several SARS-CoV-2, SARS and MERS-related coronaviruses polymerases shows that these residues are conserved in all these viruses, opening the possibility to use sofosbuvir against these highly infectious pathogens.
All Keywords
【저자키워드】 Virology, Molecular medicine, 【초록키워드】 Treatment, viruses, SARS-CoV-2, Vaccine, coronavirus, Antiviral, SARS-CoV, Infection, infections, hepatitis C virus, Pathogens, residue, polymerase, conserved, approved, the SARS-CoV-2, 【제목키워드】 sofosbuvir, Epidemic, treat, the SARS-CoV-2,
【저자키워드】 Virology, Molecular medicine, 【초록키워드】 Treatment, viruses, SARS-CoV-2, Vaccine, coronavirus, Antiviral, SARS-CoV, Infection, infections, hepatitis C virus, Pathogens, residue, polymerase, conserved, approved, the SARS-CoV-2, 【제목키워드】 sofosbuvir, Epidemic, treat, the SARS-CoV-2,